Chronic Stable Angina-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017
[Report Updated: 30-05-2017]

Published by Delve Insight: 30 May 2017 | 86391

Sorry, this report is no longer available.

We may have other suitable reports available - try Searching for Chronic
or contact our sales team for personal assistance: phone +44 (0)7887945155 or email pdb@bioportfolio.co.uk.

Introduction

DelveInsight’s Report, “Chronic Stable Angina-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2016”, provides comprehensive insights about the marketed drugs, drug sales, Phase III pipeline drugs and their API Manufacturersacross the globe. A key objective of the Chronic Stable Angina Report is to understand the market and pipeline status of the drugs around the Chronic Stable Angina to explore the generic development opportunities, licensing opportunities and to gain competitive advantage on designing pipeline startegies. The DelveInsight’s Report provides the historical and forecasted sales of the drugs till 2018. The Report gives insights into patents providing the patent protection data and marketing exclusivity of all the drugs across the Chronic Stable Angina. While the leading brands, companies and chemicals are considered thoroughly, DelveInsight’s report also provides details on the Global API Manufacturers across the globe covering Drug Master Filings of US, Europe and API Manufacturers in Asia specifically China and India.

Please note:This report requires certain updates. We have all the information available but require 48-72 Hours to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE:

• A snapshot of the global Market and Phase III therapeutics scenario for Chronic Stable Angina.

• A review of the marketed products under prescription for Chronic Stable Angina, regulatory information and marketing status.

• Coverage of global patent coverage and detailed commentaries on the US patent challenges.

• Graphical representation of investigational products for patent expiry and market exclusivities across the globe.

• Product profiles for marketed products for Chronic Stable Angina with complete description of mechanism of action, therapeutic class, target, route(s) of administration and chemical details.

• Coverage of API Manufacturers for Chronic Stable Angina drugs in the United States, Europe and Asian Regions with location details.

• Coverage of Regulatory filings in theUS, Europe, and Asia specifically India and China for Chronic Stable Angina drugs.

• Coverage of Route of Synthesis of Active Pharmaceutical Ingredient associated with Chronic Stable Angina drugs.

• Coverage of Chronic Stable Angina Phase III pipeline products featuring sections on product description, mechanism of action, Chemical details and research & development progress.

• Coverage of the United States Drug Master File (US DMF) available for Phase III Pipeline Drugs.

• Key discontinued Marketed products.

• Global Sales Figure to 2018.

Reasons to buy

• Evaluate the marketing status and exclusivity details of Chronic Stable Angina key products to exploit opportunities for generic drug development opportunities.

• Identify and understand important and diverse types of therapeutics under Phase III development for Chronic Stable Angina.

• Design effective counter-strategies to gain competitive advantage by identifying the key patent expiry details and exclusivity with respect to Chronic Stable Angina.

• API intelligence over marketed drugs forChronic Stable Anginaand gaining primary intelligence over active ingredients manufacturers across the globe.

• API intelligence over leading Phase III Pipeline drugs.

• Develop and designstrategies by identifying the API manufacturers for Phase III Pipeline products to enhance and expand business potential and scope.

• Understanding the scope of the Phase III Drugs with nil regulatory filings.

• Understanding the chemical route of synthesis of approved drugs for Chronic Stable Angina.

• Uncovering opportunities in the rapidly growing US market.

Table of Contents
for Chronic Stable Angina-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

List Of Tables
in Chronic Stable Angina-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

• Chronic Stable Angina Therapeutic Market, US, Marketed Drugs by Application Type, 2017

• Chronic Stable Angina Therapeutic Market, US, Marketed Drugs by Marketing Status, 2017

• Chronic Stable Angina Therapeutic Market, US, (Year), 2017

• Chronic Stable Angina Marketed Drugs, API Manufacturers by US DMF Status, 2017

• Chronic Stable Angina Marketed Drugs, US DMF Status Drug Specific (Number), 2017

• Chronic Stable Angina Drugs, API Manufacturers, Europe by Country, 2017

• Chronic Stable Angina Drugs, API Manufacturers, India by State, 2017

• Chronic Stable Angina Drugs, API Manufacturers, China by Province, 2017

• Chronic Stable Angina Drugs, API Manufacturers by Geography 2017

• Chronic Stable Angina Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017

• Chronic Stable Angina Therapeutic Market, Global Sales-2018 (in million USD)

• API Manufacturers for Drug, 2017

• Phase III Drugs for Chronic Stable Angina, 2017

• Discontinued Drugs for Chronic Stable Angina, 2017

List Of Figures, Charts and Diagrams
in Chronic Stable Angina-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017 [Report Updated: 30-05-2017]

• Chronic Stable Angina Therapeutic Market, US, Marketed Drugs by Application Type (%), 2017

• Chronic Stable Angina Therapeutic Market, US, Marketed Drugs by Marketing Status (%), 2017

• Chronic Stable Angina Therapeutic Market, US, (Year), 2017

• Chronic Stable Angina Marketed Drugs, API Manufacturers by US DMF Status (%), 2017

• Chronic Stable Angina Marketed Drugs, US DMF Status Drug Specific (Number), 2017

• Chronic Stable Angina Drugs, API Manufacturers, Europe by Country, 2017

• Chronic Stable Angina Drugs, API Manufacturers, India by State, 2017

• Chronic Stable Angina Drugs, API Manufacturers, China by Province, 2017

• Chronic Stable Angina Drugs, API Manufacturers by Geography 2017

• Chronic Stable Angina Phase III Pipeline Drugs, US DMF Status Drug Specific (Number), 2017

• Chronic Stable Angina Therapeutic Market, Global Sales 2018 (in million USD)

• Drug, Patent/Exclusivity Expiry (Year), 2017

Additional Details

Publisher

Delve Insight

Publisher Information

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.



We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

Reference

86391 | DIIR2017225

Number of Pages

100

Report Format

PDF

Delve Insight Reports

Related Reports

TitleDate PublishedPrice fromMore Details
SAVE 12% today! Global Acute and Chronic Myelogenous Leukemia Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,316 (normally
USD $1,495)
More Info
SAVE 12% today! Global Chronic Kidney Disease Partnering 2010 to 2016
The Global Therapy Partnering Terms and Agreements since 2010 report provides understanding and acce...
01 Oct 2016 by Current Partnering USD $1,316 (normally
USD $1,495)
More Info
SAVE 12% today! The Outlook for Wearable Health Tech in Managing Chronic Disease
IntroductionWearable tech – the new golden ticket for patient adherence?Wearable technology is being...
01 May 2016 by FirstWord Pharma USD $612 (normally
USD $695)
More Info
SAVE 12% today! Chronic Obstructive Pulmonary Disorder (COPD): Update Bulletin [Feb 2016]
IntroductionThis edition presents key opinion leader (KOL) views on recent developments in the chron...
01 Feb 2016 by FirstWord Pharma USD $876 (normally
USD $995)
More Info
SAVE 12% today! Chronic Lymphocytic Leukaemia: Update Bulletin [Feb 2016]
IntroductionGain new KOL insights on the latest events with the potential to shape the targeted trea...
01 Feb 2016 by FirstWord Pharma USD $876 (normally
USD $995)
More Info
SAVE 12% today! Chronic Lymphocytic Leukaemia: KOL Insight
IntroductionIn the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s...
01 Sep 2015 by FirstWord Pharma USD $6,952 (normally
USD $7,900)
More Info
SAVE 12% today! Chronic Obstructive Pulmonary Disorder (COPD): KOL Insight
IntroductionCombination therapy is set to take centre stage in the treatment of COPD as leading comp...
20 Apr 2015 by FirstWord Pharma USD $6,952 (normally
USD $7,900)
More Info
SAVE 12% today! Chronic Lymphocytic Leukaemia: KOL Insight
IntroductionChronic lymphocytic leukaemia (CLL) is the most common of the leukaemias, but until rece...
27 May 2014 by FirstWord Pharma USD $6,952 (normally
USD $7,900)
More Info
SAVE 12% today! Chronic Obstructive Pulmonary Disorder (COPD) - KOL Insight and Consensus Outlook
IntroductionThe prevalence of Chronic Obstructive Pulmonary Disorder (COPD) is increasing globally, ...
20 Jan 2014 by FirstWord Pharma USD $6,596 (normally
USD $7,495)
More Info
SAVE 12% today! Physician Views: Life after Gleevec in the chronic myeloid leukaemia (CML) market?
ScopeNovartis' Gleevec is widely credited as being one of the most important drug launches of all ti...
01 Jun 2013 by FirstWord Pharma USD $612 (normally
USD $695)
More Info

This report is published by Delve Insight

DelveInsight is a leading Business Consulting and Market Research Firm. We combine industry expertise with probing market insights in innovative ways to deliver enduring results to deliver critical information to leading decision makers.

We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. DelveInsight is a knowledge partner for business strategy and market research across the drug value chain.

We Stock...